

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

01722906

09/892,981

APPLICANT

Roland Gerritsen van der Hoop

FILING DATE

GROUP

June 27, 2001

1614

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

RECEIVED
TECH CENTER 1500/2900
03 FEB 20 PM 1:31

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	TAB	PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
	1.	3	1	2	1	0	4	2	02/11/64	Ercoli			
	2.	4	0	8	3	9	7	3	04/11/78	Van der Vies			
	3.	4	4	4	2	0	9	4	04/10/84	Atkinson, et al.			
	4.	4	4	9	6	5	5	6	01/29/85	Orentreich			
	5.	4	5	6	3	4	7	3	01/07/86	Hofman, et al.			
	6.	4	7	8	8	0	6	2	11/29/88	Gale, et al.			
	7.	4	8	6	3	9	7	0	09/05/89	Patel, et al.			
	8.	5	0	2	3	2	5	2	06/11/91	Hseih			
	9.	5	0	2	6	6	9	2	06/25/91	Juno, et al.			
	10.	5	0	5	3	2	2	7	10/01/91	Chiang, et al.			
	11.	5	0	5	9	6	0	3	10/22/91	Rubin			
	12.	5	1	1	6	8	2	8	05/26/92	Mijra, et al.			
	13.	5	1	5	2	8	9	7	10/06/92	Ebert, et al.			
	14.	5	2	5	6	6	5	2	10/26/93	El-Rashidy			
	15.	5	3	2	4	5	2	1	06/28/94	Gertner, et al.			
	16.	5	3	3	2	5	7	7	07/26/94	Gertner, et al.			
	17.	5	3	4	0	5	8	4	07/23/94	Spicer, et al.			
	18.	5	3	4	0	5	8	5	08/23/94	Pike, et al.			
	19.	5	3	4	0	5	8	6	08/23/94	Pike, et al.			
	20.	5	3	4	6	9	0	1	09/13/94	Bell, et al.			
	21.	5	3	6	2	4	9	7	11/08/94	Yamada, et al.			
	22.	5	4	6	0	8	2	0	10/24/95	Ebert, et al.			
	23.	5	5	5	0	1	0	7	08/27/96	Labrie			
	24.	5	6	1	0	1	5	0	03/11/97	Labrie			
	25.	5	6	2	9	0	1	9	05/13/97	Lee, et al.			
	26.	5	6	4	8	3	5	0	07/15/97	De Lignieres			
	27.	5	6	6	5	3	7	7	09/09/97	Gonella			
	28.	5	7	3	1	3	0	3	03/24/98	Hsieh			
	29.	5	7	8	0	0	5	0	07/14/98	Jain, et al.			
	30.	5	7	8	3	2	0	8	07/21/97	Venkateshwaran, et al.			
	31.	5	8	0	7	8	4	9	09/15/98	Labrie			
	32.	5	8	4	9	7	2	9	12/15/98	Zoumas, et al.			
	33.	5	8	5	5	9	0	5	01/05/99	Oettel, et al.			
EXAMINER									DATE CONSIDERED				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

01722906

09/892,981

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Roland Gerritsen van der Hoop

FILING DATE

GROUP

June 27, 2001

1614

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	TAB	PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
	34.	5	8	5	5	9	2	0	01/05/99	Chein			
	35.	5	8	8	2	6	7	6	03/16/99	Lee, et al.			
	36.	5	9	0	2	6	0	3	05/11/99	Chen, et al.			
	37.	5	9	0	6	8	3	0	05/25/99	Farinas, et al.			
	38.	6	0	2	4	9	7	4	02/15/00	Li			
	39.	6	0	3	6	9	7	7	03/14/00	Drizen, et al.			
	40.	6	1	1	7	4	4	6	09/12/00	Place			
	41.	6	1	3	9	8	7	3	10/31/00	Hughes, Jr., et al.			
	42.	6	2	2	1	3	7	9	04/24/01	Place			
	43.	6	2	2	5	2	9	9	05/01/01	Golbs, et al.			
	44.	6	2	2	8	8	5	2	05/08/01	Shaak			
	45.	6	2	6	7	9	8	4	07/31/01	Beste, et al.			
	46.	6	3	1	9	9	1	3	11/20/01	Mak, et al.			
	47.	6	3	4	2	2	5	0	01/29/02	Masters			
	48.	0	2	0	4	0	6	5	01/10/02	Kanios			
EXAMINER										DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													



Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	APPLICANT Roland Gerritsen van der Hoop	
	FILING DATE June 27, 2001	GROUP 1614

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	TAB	DOCUMENT NUMBER	PUB DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION
	49.	9 1 6 7 7 8	01/30/63	UK			
	50.	2 5 1 5 0 4 1	04/29/83	FR			
	51.	2 5 1 8 8 7 9	07/01/83	FR w/English Translation			
	52.	2 5 1 9 2 5 2	07/08/83	FR w/English Translation			
	53.	2 7 0 5 5 7 2	12/02/94	FR			
	54.	3 2 3 8 9 8 4	10/21/82	DE A1			
	55.	9 3 2 5 1 6 8	12/23/93	WO A1			
	56.	9 6 2 0 6 9 9	07/11/96	WO A1			
	57.	9 6 3 6 3 3 9	11/21/96	WO A2			
	58.	9 8 0 6 4 0 4	02/19/98	WO A1			
	59.	0 0 4 0 2 3 0	07/13/00	WO A2			
	60.	0 0 7 4 6 8 4	12/14/00	WO A1			
	61.	0 0 7 6 5 2 2	12/21/00	WO A1			
	62.	0 2 1 1 7 6 8	02/14/02	WO A1			
	63.	0 2 1 7 9 2 6	03/07/02	WO A1			
	64.	0 2 1 7 9 2 7	03/07/02	WO A1			
	65.	0 2 1 7 9 6 7	03/07/02	WO A1			
	66.	0 1 9 7 7 5 3	10/15/86	EP A2			
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Roland Gerritsen van der Hoop	
	FILING DATE June 27, 2001	GROUP 1614

(37 CFR 1.98 (b))

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

67.	Yu, et al., <i>Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application</i> , <u>Journal of Clinical Pharmacology</u> , Vol. 37, pp. 1129-1138 (1997).
68.	Yu, et al., <i>Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men</i> , <u>Journal of Clinical Pharmacology</u> , Vol. 37, pp. 1139-1145 (1997).
69.	<i>Testoderm</i> , Physicians' Desk Reference, Alza 517-520.
70.	Cunningham, et al., <i>Testosterone Transdermal Delivery System</i> , <u>Pharmacology, Biology, and Clinical Applications of Androgens</u> , Vol. 42, pp. 437-447 (1996 Wiley-Liss, Inc).
71.	Carey, et al., <i>Transdermal Testosterone Treatment of Hypogonadal Men</i> , <u>The Journal of Urology</u> , Vol. 140, pp. 76-79, (July 1988).
72.	Bals-Pratsch, et al., <i>Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year</i> , <u>ACTA Endocrinologica (COPENH)</u> , Vol. 118, pp. 7-13 (1988).
73.	Meikle, et al., <i>Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism</i> , <u>Pharmacology, Biology, and Clinical Applications of Androgens</u> , Vol. 43, pp. 449-457 (1996 Wiley-Liss, Inc.).
74.	Arver, et al., <i>Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men</i> , <u>Clinical Endocrinology</u> , Vol. 47, pp. 727-737 (1997).
75.	Brocks, et al., <i>Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose</i> , <u>Journal of Clinical Pharmacology</u> , Vol. 36, pp. 732-739 (1996).
76.	Cofrancesco, Jr., et al., <i>Transdermal Testosterone Delivery Systems</i> , <u>The Endocrinologist</u> , Vol. 6, No. 3, pp. 207-213 (1996).
77.	Mazer, et al., <i>Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men</i> , <u>Journal of Controlled Release</u> , Vol. 19, pp. 347-361 (1992).
78.	Schurmeyer, et al., <i>Comparative Pharmacokinetics of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men</i> , <u>International Journal of Andrology</u> , Vol. 7, pp. 181-187 (1984).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	APPLICANT Roland Gerritsen van der Hoop	
	FILING DATE June 27, 2001	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

79.	Behre, et al., <i>Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester</i> , <u>Journal Of Endocrinology And Metabolism</u> , Vol. 75, No. 5, pp. 1204-1210 (1992).
80.	Jockenhovel, et al., <i>Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men</i> , <u>Clinical Endocrinology</u> , Vol. 45, pp. 61-71 (1996).
81.	<i>Sexual Dysfunction in the Male – Sexual Arousal Disorder</i> , <u>The Merck Manual</u> , Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992).
82.	Weinbauer, et al., <i>Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate and Dihydrotestosterone Enanthate in Non-Human Primates</i> , <u>ACTA Endocrinologica (COPENH)</u> , Vol. 122, No. 4, pp. 432-442 (1990).
83.	Bagatell, et al., <i>Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men</i> , <u>Journal Of Clinical Endocrinology And Metabolism</u> , Vol. 78, No. 3, pp. 711-716 (1994).
84.	Bancroft, <i>Endocrinology of Sexual Function</i> , <u>Clinics In Obstetrics And Gynecology</u> , Vol. 7, No. 2, pp. 253-281 (August 1980).
85.	Damassa, et al., <i>Sex Hormone-Binding Globulin and Male Sexual Development</i> , <u>Neuroscience And Biobehavioral Reviews</u> , Vol. 19, No. 2, pp. 165-175 (1995).
86.	Wang, et al., <i>Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men – A Clinical Research Center Study</i> , <u>Journal Of Clinical Endocrinology And Metabolism</u> , Vol. 83, No. 8, pp. 2749-2757 (August 1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	APPLICANT R. Dudley, et al.	
	FILING DATE June 27, 2001	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

87.	Barrett-Connor, et al., <i>Cognitive Function and Endogenous Sex Hormones in Older Women</i> , <u>J. Am. Geriatr. Soc.</u> , Vol. 47, No. 11, pp.1289-93 (November 1999).
88.	Javanbakht, et al., <i>Pharmacokinetics of a Novel Testosterone Matrix Transdermal System in Healthy, Premenopausal Women and Women Infected with the Human Immunodeficiency Virus</i> , <u>Journal of Clinical Endocrinology and Metabolism</u> , Vol. 85, No. 7, pp. 2395-2401 (July 2000).
89.	Shifren, et al, <i>Transdermal Testosterone Treatment in Women with Impaired Sexual Function After Oophorectomy</i> , <u>The New England Journal Of Medicine</u> , Vol. 343, No. 10, pp. 682-688 (September 7, 2000). [Abstract]
90.	Guzick, et al., <i>Sex, Hormones, and Hysterectomies</i> , <u>The New England Journal Of Medicine</u> , Vol. 343, No. 10, pp. 730-731 (September 7, 2000). [Abstract]
91.	ENDO 99: <i>Testosterone Patch Effective for Diminished Sexual Function in Surgically Menopausal Women</i> , <u>Doctor's Guide To The Internet</u> , http://www.docguide.com (June 15,1999).
92.	Kuhn, et al., <i>Percutaneous Androgen Treatment for Male Hypogonadism. Compared Efficacy of Testosterone and Dihydrotestosterone: Study of 40 Observations</i> , <u>Endocrinologie</u> , Vol. 14, No. 11, pp. 1031-1036 (1986) (English Translation).
93.	Wang, et al., <i>Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study</i> , <u>The Journal Of Endocrinology And Metabolism</u> , Vol. 85, No. 3, pp. 964-969 (March 2000).
94.	Marin, et al., <i>Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues</i> , <u>European Journal of Medicine</u> , Vol. 1, No. 6, pp. 329-336 (October 1992).
95.	Morley, et al., <i>Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy</i> , <u>J. Lab. Clin. Med.</u> , Vol. 135, No. 5, pp. 370-378 (May 2000).
96.	Jaffe, et al., <i>Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men</i> , <u>Horm. Res.</u> , Vol. 41, pp. 215-217 (1994).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	APPLICANT Roland Gerritsen van der Hoop	
	FILING DATE June 27, 2001	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

97.	Sherwin, <i>Affective Changes with Estrogen and Androgen Replacement Therapy in Surgically Menopausal Women</i> , <u>Journal Of Affective Disorders</u> , Vol. 14, pp. 177-187 (1988).
98.	Sherwin, <i>Estrogen and/or Androgen Replacement Therapy and Cognitive Functioning in Surgically Menopausal Women</i> , <u>Psychoneuroendocrinology</u> , Vol. 13, No. 4, pp. 345-357 (March 1988).
99.	Sherwin, <i>Sex Hormones and Psychological Functioning in Postmenopausal Women</i> , <u>Experimental Gerontology</u> , Vol. 29, Nos. 3&4, pp. 423-430 (May-August 1994).
100.	Need, et al., <i>Double-Blind Placebo-Controlled Trial of Treatment of Osteoporosis with the Anabolic Nandrolone Decanoate</i> , <u>Osteoporosis Int.</u> , Supplement 1: S218-222 (1993).
101.	Raisz, et al., <i>Comparison of the Effects of Estrogen Alone and Estrogen Plus Androgen on Biochemical Markers of Bone Formation and Resorption in Postmenopausal Women</i> , <u>Journal Of Clinical Endocrinology And Metabolism</u> , Vol. 81, No. 1, pp. 37-43 (January 1996).
102.	Cashdan, <i>Hormones, Sex and Status in Women</i> , <u>Hormones And Behavior</u> , Vol. 29, pp. 354-366 (September 1995).
103.	Morrison, <i>Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women</i> , <u>Psychopharmacology Bulletin</u> , Vol. 33, No. 2, pp. 293-296 (1997).
104.	Gruber, et al., <i>Effect of Percutaneous Androgen Replacement Therapy on Body Composition and Body Weight in Postmenopausal Women</i> , <u>Maturitas</u> , Vol. 29, pp. 253-259 (June 1998).
105.	Buckler, et al., <i>The Effects of Low-Dose Testosterone Treatment on Lipid Metabolism, Clotting Factors and Ultrasonographic Ovarian Morphology in Women</i> , <u>Clinical Endocrinology</u> , Vol. 49, pp. 173-178 (1997).
106.	Douchi, et al., <i>Serum Androgen Levels and Muscle Mass in Women with Polycystic Ovary Syndrome</i> , <u>Obstetrics & Gynecology</u> , Vol. 94, No. 3, pp. 337-340 (1999).
107.	Vermeulen, et al., <i>Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins</i> , <u>Maturitas</u> , Vol. 7, pp. 281-287 (1985).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Roland Gerritsen van der Hoop	
	FILING DATE June 27, 2001	GROUP 1614

(37 CFR 1.98 (b))

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

108.	Davidson, et al., <i>Hormonal Changes and Sexual Function in Aging Men</i> , <u>Journal Of Clinical Endocrinology And Metabolism</u> , Vol. 57, No. 1, pp. 71-77 (1983).
109.	Basson , <i>Androgen Replacement for Women</i> , <u>Canadian Family Physician</u> , Vol. 45, pp. 2100-2107 (September 1999).
110.	Persky, et al., <i>The Relation of Plasma Androgen Levels to Sexual Behaviors and Attitudes of Women</i> , <u>Psychosomatic Medicine</u> , Vol. 44, No. 4, pp. 305-319 (September 1982).
111.	de Lignieres, et al., <i>Treatment of Male Hypogonadism by Topical Administration of Androgens</i> , pp. 273-283 (1980).
112.	Carlstrom, et al., <i>Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function</i> , <u>International Journal Of Andrology</u> , Vol. 13, pp. 67-73 (1990).
113.	Ding, et al., <i>Sex Hormone-Binding Globulin Mediates Prostate Androgen Receptor Action via a Novel Signaling Pathway</i> , <u>Endocrinology</u> , Vol. 139, No. 1, pp. 213-218 (January 1998).
114.	Lagiou, et al., <i>Serum Steroids in Relation to Benign Prostatic Hyperplasia</i> , <u>Oncology</u> , Vol. 54, No. 6, pp. 497-501 (November-December 1997).
115.	Nakhla, et al, <i>Stimulation of Prostate Cancer Growth by Androgens and Estrogens Through the Intermediacy of Sex Hormone-Binding Globulin</i> , <u>Endocrinology</u> , Vol. 137, No. 10, pp. 4126-4129 (October 1996).
116.	Gann, et al., <i>Prospective Study of Sex Hormone Levels and Risk of Prostate Cancer</i> , <u>Journal of National Cancer Institute</u> , Vol. 88, No. 16, pp. 1118-1126 (August 21, 1996). [Abstract]
117.	Liao, J., <i>Androgen Action: Molecular Mechanism and Medical Application</i> , <u>J. Formos Med. Assoc.</u> , Vol. 93, No. 9, pp. 741-751 (September 1994).
118.	<i>Testosterone Gel May Help Men with Low Sex Drive</i> , WRAL ONLINE, http://www.wral-tv.com/features/healthteam/1997/0814-tgel/ (August 14, 1997).
119.	Davis, et al., <i>Testosterone Enhances Estradiol's Effects on Postmenopausal Bone Density and Sexuality</i> , <u>Maturitas</u> , Vol. 21, No. 3, pp. 227-36 (April 1995).

EXAMINER

DATE CONSIDERED


EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	APPLICANT Roland Gerritsen van der Hoop	
	FILING DATE June 27, 2001	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

120.	Schreiner-Engel, et al., <i>Low Sexual Desire in Women: the Role of Reproductive Hormones</i> , <u>Hormones and Behavior</u> , Vol. 23, No. 2, pp. 221-234 (June 1989).
121.	Kirschner, et al., <i>Androgen-Estrogen Metabolism in Women with Upper Body Versus Lower Body Obesity</i> , <u>Journal Of Clinical Endocrinology And Metabolism</u> , Vol. 70, No. 2, pp. 473-479 (February 1990).
122.	Alexander, et al., <i>Testosterone and Sexual Behavior in Oral Contraceptive Users and Nonusers: A Prospective Study</i> , <u>Hormones and Behavior</u> , Vol. 24, No. 3, pp. 388-402 (September 1990).
123.	Studd, et al., <i>The Relationship Between Plasma Estradiol and the Increase in Bone Density in Postmenopausal Women After Treatment with Subcutaneous Hormone Implants</i> , <u>American Journal Of Obstetrics And Gynecology</u> , Vol. 163, No. 5 (Part 1), pp. 1474-1479 (November 1990).
124.	Myers, et al., <i>Effects of Estrogen, Androgen, and Progestin on Sexual Psychophysiology and Behavior in Postmenopausal Women</i> , <u>Journal of Clinical Endocrinology And Metabolism</u> , Vol. 70, No. 4, pp. 1124-1131 (April 1990).
125.	Gouchie, et al., <i>The Relationship Between Testosterone Levels and Cognitive Ability Patterns</i> , <u>Psychoneuroendocrinology</u> , Vol. 16, No. 4, pp. 323-334 (1991).
126.	Garnett, et al., <i>A Cross-Sectional Study of the Effects of Long-Term Percutaneous Hormone Replacement Therapy on Bone Density</i> , <u>Obstetrics & Gynecology</u> , Vol. 78, No. 6, pp. 1002-1007 (December 1991).
127.	Eriksson, et al., <i>Serum Levels of Androgens are Higher in Women with Premenstrual Irritability and Dysphoria Than in Controls</i> , <u>Psychoneuroendocrinology</u> , Vol. 17, Nos. 2-3, pp. 195-204 (May-July 1992).
128.	Garnett, et al., <i>The Effects of Plasma Estradiol Levels on Increases in Vertebral and Femoral Bone Density Following Therapy with Estradiol and Estradiol with Testosterone Implants</i> , <u>Obstetrics and Gynecology</u> , Vol. 79, No. 6, pp. 968-972 (June 1992).
129.	Savvas, et al., <i>Increase in Bone Mass after One Year of Percutaneous Oestradiol and Testosterone Implants in Post-Menopausal Women Who Have Previously Received Long-Term Oral Oestrogens</i> , <u>British Journal of Obstetrics Gynaecology</u> , Vol. 99, No. 9, pp. 757-760 (September 1992).
130.	Dr. N's Menopause & Hysterectomy Resource Page, http://www.menopausehysterectomy.com/methods.htm .
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	




Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Roland Gerritsen van der Hoop	
(37 CFR 1.98 (b))	FILING DATE June 27, 2001	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

131.	Testocrema Transdermal Testosterone Is New, <u>Preventive Medicine Clinic Of Monterey</u> , http://www.wellnessmd.com/testo.html .
132.	Product Information - Testoderm TTS, <u>Physicians' Desk Reference</u> , Alza pp. 517-520.
133.	Kuhn, et al., Gynecomastia: Effect of Prolonged Treatment with Dihydrotestosterone by the Percutaneous Route, <u>Presse Medicine</u> , Vol. 12, No. 1, pp. 21-25 (January 8, 1983). [Abstract]
134.	SEPA Testosterone Transdermal Gel Receives Application By FDA, <u>Doctor's Guide Global Edition</u> , http://pslgroup.com/dg/123aa.htm (January 15, 1997).
135.	Press Release - 10/21/99 -- MacroChem Awarded U.S. Patent Covering Transdermal Hormone Replacement Incorporating Proprietary SEPA® Technology and Hormonally Active Drugs Such as Testosterone, Estradiol and Progesterone, http://www.mchm.com/press/pr24.asp (October 21, 1999).
136.	AndrosteDERM, http://www.gethugene.net/androderm1.htm .
137.	Male Hormone Patch Approved, <u>Nupharm</u> , http://www.nupharm.com/malehorm.htm
138.	SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available, <u>International Association of Physicians in AIDS Care</u> , http://www.iapac.org/clinmgt/compnews/sb061297.html (June 12, 1997).
139.	Impotence Treatments, <u>Impotence World Association</u> , http://www.impotenceworld.org/treatment.htm (2000).
140.	Andro Gel, <u>Netrition</u> , http://www.netrition.com/andro_gel_page.html (1997-1998).
141.	Prospectus - Cellegy Pharmaceuticals, Inc., OPPENHEIMER & CO., pp. 1-4, 21-28 (1997).
142.	Cellegy Pharmaceuticals Market Opportunities, CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market.html (1997).
143.	Itoh, et al., The Assessment of Bioavailable Androgen Levels from the Serum Free Testosterone Level, <u>Nippon Naibunpi Gakkai Zasshi</u> , Vol. 67, No. 1, pp. 23-32 (January 20, 1991). [Abstract]
144.	Gaidano, et al., Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty, <u>Clinical Chimica Acta</u> , Vol. 100, No. 2, pp. 91-97 (January 15, 1980).
145.	Zmuda, et al., Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men, <u>Metabolism</u> , Vol. 45, No. 8, pp. 935-939 (August 1996).
EXAMINER	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
DATE CONSIDERED	



Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
	01722906	09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Roland Gerritsen van der Hoop	
(37 CFR 1.98 (b))	FILING DATE	GROUP
	June 27, 2001	1614

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

146.	Wang, et al., <i>Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone</i> , <u>Journal Of Clinical Endocrinology And Metabolism</u> , Vol. 53, No. 5, pp. 1021-1024 (November 1981).
147.	Fahrner, et al., <i>Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG)</i> , <u>International Journal Of Sports Medicine</u> , Vol. 19, No. 1, pp. 12-15 (January 1998). [Abstract]
148.	Masters, et al., <i>Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol</i> , <u>Clinical Chemistry</u> , Vol. 35, No. 6, pp. 979-984 (June 1989).
149.	Pirke, et al., <i>Age Related Changes and Interrelationships Between Plasma Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males</i> , <u>ACTA Endocrinologica (COPENH)</u> , Vol. 74, No. 4, pp. 792-800 (December 1973).
150.	Lewis, et al., <i>Proceedings: Age-Related Changes in Serum 5alpha-dihydrotestosterone and Testosterone in Normal Men</i> , <u>Journal Of Endocrinology</u> , Vol. 67, No. 2, pg. 15P (November 1975).
151.	Belgorosky, et al., <i>Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones</i> , <u>J. Steroid Biochem.</u> , Vol. 18, No. 6, pp. 783-787 (June 1983).
152.	Longcope, et al., <i>Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men</i> , <u>Journal Of Clinical Endocrinology And Metabolism</u> , Vol. 71, No. 6, pp. 1442-1446 (December 1990).
153.	Willemse, et al., <i>No Change in Plasma Free Testosterone Ratio and Plasma Sex Hormone-Binding Globulin Concentration During hCG Stimulation</i> , <u>Journal Of Clinical Endocrinology And Metabolism</u> , Vol. 58, No. 6, pp. 1193-1196 (June 1984).
154.	Valero-Politi, et al., <i>Annual Rhythmic Variations of Folitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men</i> , <u>Clinica Chimica Acta</u> , Vol. 271, No. 1, pp. 57-71 (March 9, 1998).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO - 1449 (Modified)


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Roland Gerritsen van der Hoop	
	FILING DATE June 27, 2001	GROUP 1614

(37 CFR 1.98 (b))

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

155.	Wang, et al., <i>Pharmacokinetics Of Transdermal Testosterone Gel In Hypogonadal Men</i> , ENDO '98 SUBMISSION PROGRAM, 1998N ABSTRACT FORM.
156.	Manos, <i>FDA Approves Gel to Treat Low Testosterone Levels</i> , www.testocrema.com (Downloaded 5/09/01).
157.	Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men, Fertility Industry News, www.INCIID.com (August 19, 1998).
158.	Lacayo, <i>Are You Man Enough?</i> , <i>Time Europe</i> , www.Time.com , Vol. 155, No. 16 (April 24, 2000).
159.	MacroChem Accelerates Development of Top For Impotence, www.pslgroup.com (April 10, 1997).
160.	Kaufman, <i>Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation</i> , <i>International Journal of Impotence Research</i> , Vol. 12, Supplement 3, p. S75 (B9) (September 2000).
161.	Longstreth, et al., <i>Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment</i> , Unimed Pharmaceuticals (October 31, 2000)
162.	Ringham, et al., <i>Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel In Hypogonadal Men</i> , Unimed Pharmaceuticals (October 31, 2000).
163.	Swerdloff, et al., <i>Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men</i> , 2347 Male Reproductive Poster Session, Board 578 (June 22, 2000).
164.	Wang, et al., <i>Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men</i> , 2348 Male Reproductive Poster Session, Board 579 (June 22, 2000).
165.	Wang, et al., <i>Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men</i> , <i>Clinical Endocrinology</i> , Vol. 54, pp. 1-13 (2001). [Abstract]
166.	Wang, et al., <i>Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men</i> , <i>Basic Science: Reproduction-Gonadal Control (Male)</i> , Male Reproduction Oral Session, No. 1360 (June 24, 2000).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Roland Gerritsen van der Hoop	
	FILING DATE June 27, 2001	GROUP 1614

(37 CFR 1.98 (b))

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

167.	Bentley Pharmaceuticals Announces License Agreement for Its Topical Testosterone Gel Formulation; Li, www.UVentures.com (December 18, 2000).
168.	Riggs, Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel, Unimed News Release, pp. 1-2 (March 31, 1997).
169.	AndroGel® (Testosterone Gel) CIII Physicians Desk Reference, Issued 12/00
170.	Hormone Therapy, BioSante Pharmaceuticals (downloaded 10/02)
171.	Swerdlhoff, et al., Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men, <u>Clinical Science: Reproduction (Male)-Prostate</u> , Male Reproduction Poster Session, No. 2347 (June 22, 2000).
172.	<u>Trials for the Treatment of Wasting, AIDS Treatment Data Network</u> , www.aidsinfonyc.org (Downloaded 10/8/98).
173.	De Lunardo, et al., Determination of Acceptability of 2 Cutaneous Estradiol Gels, In A Dose of 1.5 mg Daily, <u>J. Gynecol. Obstet. Biol. Reprod. (Paris)</u> , Vol. 29, No. pp. 509-516, (September 2000). [Abstract]
174.	Zartarian, et al., Comparative Evaluation of the Acceptability of a New Estradiol Gel TX11323(A) and a Reference Gel, <u>J. Gynecol. Obstet. Biol. Reprod. (Paris)</u> , Vo. 25, No. 5, pp. 451-456 (1996). [Abstract]
175.	Fournier, et al., Value of a Percutaneous Estrogen Solution in Stopping Lactation, <u>Rev. Fr. Gynecol. Obstet.</u> , Vol. 85, No. 12, pp. 715-719 (December 1990). [Abstract]
176.	Data Supports Safety of Estratest For Men, Doctor's Guide, www.pslgroup.com (March 9, 1998).
177.	Mollgaard, et al., Permeation of Estradiol Through the Skin – Effect of Vehicles, <u>International Journal of Pharmaceutics</u> , Vol. 15, pp. 185-197 (1983).
178.	Sitruk-Ware, Percutaneous and Transdermal Oestrogen Replacement Therapy, <u>Annals of Medicine</u> , Vol. 25, pp. 77-82 (1993).
179.	Jarkander-Rolff, et al., Transdermal Application of A Testosterone Gel – A Pharmacokinetic Study.
180.	EstroGel, www.netdoktor.dk/medicin/Fakta/EstroGel (Downloaded 6/26/01).
181.	Gennaro, Remington: The Science and Practice of Pharmacy, 20 th Edition, Chapter 44, pp. 842-843 (2000).
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

COPY

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Roland Gerritsen van der Hoop	
(37 CFR 1.98 (b))	FILING DATE June 27, 2001	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

182.	Walters, <i>Penetration Enhancers and Their Use in Transdermal Therapeutic Systems</i> , pp. 202-227 (1990).
183.	D. Osborne, et al., "Skin Penetration Enhancers Cited in the Technical Literature," <i>Pharmaceutical Technology</i> , Pp. 58, 60 62, 64 & 66 (November 1997).
184.	International Search Report – Application No. PCT/US 01/27205, Reference No. 01736544 (International Filing Date: 08/29/01).
185.	International Search Report – Application No. PCT/US 01/27202, Reference No. 01736571 (International Filing Date: 08/29/01).
186.	International Search Report – Application No. PCT/US 01/27199, Reference No. 01902267 (International Filing Date: 08/29/01).
187.	H. Ansel, <i>Introduction to Pharmaceutical Dosage Forms</i> , pp. 279-308 (1981).
188.	H. Ansel, et al., <i>Transdermal Drug Delivery Systems, Pharmaceutical Dosage Forms and Drug Delivery Systems</i> , pp. 263-278 (1999).
189.	Ghosh, et al., <i>Methods of Enhancement of Transdermal Drug Delivery: Part I, Physical and Biochemical Approaches</i> , <i>Pharmaceutical Technology</i> , pp. 73-90 (March 1993).
190.	Ghosh, et al., <i>Methods of Enhancement of Transdermal Drug Delivery: Part IIA, Chemical Permeation Enhancers</i> , <i>Pharmaceutical Technology</i> , pp. 62-90 (April 1993).
191.	Ghosh, et al., <i>Methods of Enhancement of Transdermal Drug Delivery: Part IIB, Chemical Permeation Enhancers</i> , <i>Pharmaceutical Technology</i> , pp. 68-76 (May 1993).
192.	Idson, et al., <i>Percutaneous Absorption Enhancers</i> , <i>D&CI</i> , pp. 30-33 (July 1985).
193.	Stomati, et al., <i>Effects of Hormonal Replacement Therapy on Plasma Sex Hormone-Binding Globulin, Androgen and Insulin-Like Growth Factor-1 Levels in Postmenopausal Women</i> , <i>Journal of Endocrinological Investigation</i> , Vol. 19 (No. 8), p. 535-541, (January 22, 1996).
194.	Raudaskoski, et al., <i>Sex-Hormone Binding Globulin As An Indicator of the Hepatic Impacts of Continuous Combined Hormone Replacement Regimens</i> , <i>Maturitas</i> , Vol. 29 (No. 1), p. 87-92, (January 22, 1998).
195.	O'Connor, <i>Managing Menopause - Part 2: What Are The Choices in Treatment?</i> , <i>Medicine Today</i> , Vol. 2 (No. 2), p. 30-39, (February 22, 2001).
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

copy

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Roland Gerritsen van der Hoop	
(37 CFR 1.98 (b))	FILING DATE June 27, 2001	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

196.	Barlow, et al., <i>In Vivo Observations on Testosterone and Estradiol-17beta Protein Binding in Women</i> , <u>Journal of Clinical Endocrinology and Metabolism</u> , Vol. 29 (No. 6), p. 767-776, (January 22, 1969).
197.	<i>Transdermal Testosterone</i> , Cellegy Pharmaceuticals, <u>www.Cellegy.com</u> (downloaded from internet on 10/21/02).
198.	Correspondence to FDA from Testocrema® and Citizen Petition (July 3, 2001).
199.	Correspondence to Testocrema® from FDA regarding response to Citizen's Petition (April 12, 2002).
200.	Testosterone and the Treatment of Erectile Dysfunction, <u>www.wellnessmd.com</u> (Downloaded from the internet on 10/21/02).
201.	Information on TestoCreme® from <u>www.testocrema.com</u> (Downloaded from the internet on 10/21/02).
202.	<i>Transdermal Testosterones</i> , <u>www.maxsportsmag.com</u> (Downloaded from the internet on 10/21/02).
203.	<i>New Drug Application for Testosterone Gel Accepted For Review by FDA Represents First NDA with Bentley's Proprietary CPE-215 Technology</i> , <u>Business Wire</u> (March 6, 2002).
204.	Internet information on Bentley Pharmaceuticals, <u>research.businessweek.com</u> (October 21, 2002).
205.	USPTO Word Mark Search on "CPE-215", <u>uspto.gov</u> (searched 10/21/02).
206.	Columbia Laboratories Announces European Marketing Partnership With Ardana Bioscience for Testosterone Buccal Bioadhesive Product, <u>www.bioexchange.com</u> (October 17, 2002).
207.	Testim 1% (Testosterone Gel) CIII.
208.	<u>The Merck Index, Eleventh Edition</u> , Definition of Isopropyl Myristate, pg. 821 (1989).
209.	Gennaro, et al, <u>Remington's Pharmaceutical Sciences</u> , pg. 1305, 1314-15 (1990).
210.	Langtry, et al., <i>Sildenafil: A Review of its Use in Erectile Dysfunction</i> , <u>Drugs</u> , Vol. 57, No. 6, pp. 967-989 (June 1999).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
	01722906	09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Roland Gerritsen van der Hoop	
(37 CFR 1.98 (b))	FILING DATE	GROUP
	June 27, 2001	1614

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

211.	Davis, <i>The Clinical Use of Androgens in Female Sexual Disorders</i> , <u>Journal of Sex & Marital Therapy</u> , Vol. 24, pp. 153-163 (1998).
212.	Myers, et al., <i>Effects of Estrogen, Androgen, and Progestin on Sexual Psychophysiology and Behavior in Postmenopausal Women</i> , <u>Journal of Clinical Endocrinology and Metabolism</u> , Vol. 70, No. 4, pp. 1124-1131 (1990).
213.	Furuyama, et al., <i>Radioimmunoassay for Plasma Testosterone</i> , <u>Steroids</u> , Vol. 16, No. 4, pp. 415-428 (1970). [Abstract]
214.	Miller, et al., <i>Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study</i> , <u>Journal of Clinical Endocrinology and Metabolism</u> , Vol. 83, No. 8, pp. 2717-25 (1998).
215.	Nankin, et al., <i>Daytime Titers of Testosterone, LH, Estrone, Estradiol, and Testosterone-Binding Protein: Acute Effects of LH and LH-Releasing Hormone in Men</i> , <u>Journal of Clinical Endocrinology Metabolism</u> , Vol. 41, pp. 271-81 (1975).
216.	Mather, et al., <i>Free Plasma Testosterone Levels During the Normal Menstrual Cycle</i> , <u>Journal of Endocrinol. Invest.</u> , Vol. 8, No. 5, pp. 437-41 (October 1985).
217.	Dobs, et al., <i>Pharmacokinetic Characteristics, Efficacy and Safety of Buccal Testosterone in Hypogonadal Males: A Pilot Study</i> , <u>Journal of Endocrinology & Metabolism</u> , Vol. 83, pp. 33-39 (1998).
218.	Parker, et al., <i>Experience with Transdermal Testosterone Replacement in Hypogonadal Men</i> , <u>Clinical Endocrinology (OXF)</u> , Vol. 50, pp. 57-62 (1999).
219.	Christiansen, <i>Behavioral Correlates of Testosterone</i> , <u>Testosterone: Action, Deficiency, Substitution</u> , pp. 109-111 (1998).
220.	Rosner, et al., <i>Sex Hormone-Binding Globulin Mediates Steroid Hormone Signal Trasduction at the Plasma Membrane</i> , <u>J. Steroid Biochem. Mol. Biol.</u> , Vol. 69, pp. 481-485 (1999).
221.	Petra, <i>The Plasma Sex Steroid Binding Protein (SBP or SHBG): A Critical Review of Recent Developments of the Structure, Molecular Biology, and Function</i> , <u>J. Steroid Biochem. Mol. Biol.</u> , Vol. 40, pp. 735-53 (1991).
222.	Kahn, et al., <i>Radioimmunoassay for Human Testosterone-Estradiol Binding Globulin</i> , <u>J. Clinical Endocrinology and Metabolism</u> , Vol. 54, pp. 705-710 (1982).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 01722906	SERIAL NO. 09/892,981
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Roland Gerritsen van der Hoop	
(37 CFR 1.98 (b))	FILING DATE June 27, 2001	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

223.		Bond, et al., <i>Sex Hormone Binding Globulin in Clinical Perspective</i> , <u>Acta Obstet. Gynecol. Scand.</u> , Vol. 66, pp. 255-262 (1987). [Abstract]
224.		Reilly, et al., <i>Androgenic Regulation of NO Availability in Rat Penile Erection</i> , <u>J. of Andrology</u> , Vol. 18, pp. 110-15 (1997).
225.		Park, et al., <i>Effects of Androgens on the Expression of Nitric Oxide Synthase mRNAs in Rat Corpus Cavernosum</i> , <u>BJU Int'l</u> , Vol. 83, pp. 327-33 (1999).
226.		Lugg, et al., <i>The Role of Nitric Oxide in Erectile Function</i> , <u>J. Andrology</u> , Vol. 16, pp. 2-4, (1995).
227.		Penson, et al., <i>Androgen and Pituitary Control of Penile Nitric Oxide Synthase and Erectile Function In the Rat</i> , <u>Biology of Reproduction</u> , Vol. 55, pp.567-74 (1996).
228.		Traish, et al., <i>Effects of Castration and Androgen Replacement on Erectile Function in a Rabbit Model</i> , <u>Endocrinology</u> , Vol. 140, pp. 1861-68 (1999).
229.		Baba, et al., <i>Delayed Testosterone Replacement Restores Nitric Oxide Synthase Containing Nerve Fibres and the Erectile Response in Rat Penis</i> , <u>BJU Int'l</u> , pp. 953-8 (2000).
230.		Garban, et al., <i>Restoration of Normal Adult Penile Erectile Response in Aged Rats by Long-Term Treatment with Androgens</i> , <u>Biology of Reproduction</u> , Vol. 53, pp. 1365-72 (1995).
231.		Marin, et al., <i>Androgen-dependent Nitric Oxide Release in Rat Penis Correlates with Levels of Constitutive Nitric Oxide Synthase Isoenzymes</i> , <u>Biology of Reproduction</u> , Vol. 61, pp. 1012-1016 (1999).
232.		Public Protest Documents filed on August 20, 2002 in protest of U.S. Patent Application Serial No. 09/651,777.
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

